The prostanoid DP receptor (PTGDR) is shown to be involved in the asthma patho-physiology and the results from the published genetic association studies are inconsistent. Four single nucleotide polymorphisms (SNPs) in PTGDR were genotyped in 342 and 294 families from UK and Denmark respectively. Asthma and asthma-related phenotypes were analyzed using family-based association analyses. In the UK families, a promoter polymorphism (À731A/G) showed significant associations with asthma (P ¼ 0.0022), atopic asthma (P ¼ 0.0044), bronchial hyperreactivity or BHR (P ¼ 0.00120) and strict asthma (P ¼ 0.0008). The P-values for asthma, BHR and strict asthma were significant even after the most stringent correction for the number of markers and the number of phenotypes analyzed (o0.0031). An intronic polymorphism ( þ 6651C/T) also showed significant associations with asthma (P ¼ 0.0302), atopic asthma (P ¼ 0.0131), BHR (P ¼ 0.0249) and strict asthma (P ¼ 0.0261). In the Danish families, an intronic polymorphism ( þ 6541C/T) showed significant associations with asthma (P ¼ 0.0071), atopic asthma (P ¼ 0.0348), BHR (P ¼ 0.0033) and strict asthma (P ¼ 0.0381). The results of haplotype analyses supported the ones of the single SNP analyses. Thus, we demonstrated significant evidence of association between polymorphisms in PTGDR with asthma phenotypes in the two Caucasian populations.
Introduction
Asthma is a heterogeneous disorder, likely resulting from the influence of multigenetic and environmental factors. Patho-physiological features in asthma include bronchial hyperresponsiveness (BHR), airway inflammation and elevated immunoglobulin E (IgE) levels. 1 Prostaglandin D 2 (PGD 2 ), a mast cell-derived mediator, functions to induce brochoconstriction in the human lung. 2 Endobronchial allergen challenge results in increased PGD 2 levels in asthmatic patients but not in nonasthmatic controls.
3 PGD 2 is a ligand for the prostanoid DP receptor (PTGDR), a heptahelical transmembrane G-protein-coupled receptor of 359 amino acids. 4 The mice lacking the PTGDR (PTGDR À/À mice) fail to develop bronchial hyperreactivity and show only marginal infiltration of eosinophils into the lung upon ovalbumin challenge. 5 PTGDR gene is located on chromosome 14q22.1 and genetic linkage to asthma and atopy has been demonstrated in this region. [6] [7] [8] [9] However, the results from four association studies to assess the genetic contribution of PTGDR in asthma are inconsistent. Oguma et al. 10 reported replicated associations of a PTGDR variant with asthma from six markers genotyped by using a Caucasian American population with 518 cases and 175 controls (P ¼ 0.04) and an African American population with 80 cases and 45 controls (P ¼ 0.01). Sanz et al. 11 showed the association of a PTGDR variant with asthma (P ¼ 0.007) from three markers genotyped in a Caucasian Spanish population with 118 cases and 79 controls. In contrast, Noguchi et al. 12 failed to demonstrate the associations of PTGDR variants with asthma in an asthma population of 144 Japanese families with 476 subjects; Tsai et al. 13 did not observe the significant associations with asthma in three populations analyzed: Puerto Ricans, Mexicans and African Americans. The contradictory reports may be caused by false positive/negative results, population stratification or true variability in association among different populations.
14 Thus, it is necessary to test whether PTGDR variants are associated with asthmarelated phenotypes in other populations with larger sample sizes.
Our evaluation of four PTGDR variants in a familybased association study in two large European Caucasian populations, a UK population of 342 families with 1446 subjects and a Danish population of 294 families with 1151 subjects are presented. Our results suggest that PTGDR variants are associated with asthma.
Results

Single nucleotide polymorphism association analysis
We analyzed four polymorphisms in the PTGDR gene in the two family-based populations (Table 1 ). In the family-based association analyses of the UK population, two single nucleotide polymorphisms (SNPs) demonstrated significant association with all the four phenotypes (Po0.05). Particularly, SNP 1 (À731A/G) showed strong significant association with asthma (P ¼ 0.0022), atopic asthma (P ¼ 0.0044), BHR (P ¼ 0.0020) and strict asthma (P ¼ 0.0008), respectively, ( Table 2 ). In addition, SNP 4 ( þ 6651C/T) was significantly associated with asthma (P ¼ 0.0302), atopic asthma (P ¼ 0.0131), BHR (P ¼ 0.0249) and strict asthma (P ¼ 0.0261) ( Table 2 ). In the Danish population, SNP 3 ( þ 6541C/T) demonstrated significant association with asthma (P ¼ 0.0071), atopic asthma (P ¼ 0.0348), BHR (P ¼ 0.0033) and strict asthma (P ¼ 0.0381), respectively ( Table 2) . Figure 1 shows pair-wise linkage disequilibrium (LD) (r 2 ) values for the four SNPs in the PTGDR gene in the UK and Danish populations. In the UK population, SNPs 1 (À731A/G), 2 (À338G/A) and 3 ( þ 6541C/T) were located in one block within PTGDR. In the Danish population, SNPs 1 (À731A/G), 2 (À338G/A), 3 ( þ 6541C/T) and 4 ( þ 6651C/T) were located in a single block within PTGDR.
Linkage disequilibrium
Haplotype analyses
Haplotype analyses using a sliding window approach of adjacent 2, 3 and 4 SNPs identified several significant associations (Table 3 ). In the UK population, haplotype 1_2 showed a significant association (P-global ¼ 0.00045 and P-specific ¼ 0.00049) with asthma; haplotype 1_2_3 also revealed a significant association (P-global ¼ 0.00589 and P-specific ¼ 0.00227) with asthma. Haplotype 1_2 showed a significant association (P-global ¼ 0.00555 and P-specific ¼ 0.00644) with atopic asthma; haplotype 1_2_3 revealed a significant association (P-global ¼ 0.01944 and P-specific ¼ 0.00603) with atopic asthma. Six adjacent SNP combinations with significant test result were detected (0.0014pP-globalp0.01829 and 0.0013p P-specificp0.01207) for BHR. Four adjacent SNP combinations with significant associations were detected (0.00143pP-globalp0.03628 and 0.00058pP-specificp 0.0087) for the strict definition of asthma.
Significant haplotypic associations were also detected in the Danish population (Table 3) . Haplotype 3_4 was significantly associated with asthma (P-global ¼ 0.02732 and P-specific ¼ 0.0153) and BHR (P-global ¼ 0.04454 and P-specific ¼ 0.02101), respectively. Three adjacent SNP combinations revealed the significant associations (0.01305pP-globalp0.04137 and 0.00261pP-specificp 0.01883) with strict asthma.
Discussion
We investigated the genetic association of PTGDR with four asthma-related phenotypes in a family-based association analysis of two European Caucasian populations involving 342 UK families and 294 Danish families.
In the UK population, we detected significant associations between PTGDR variants and all the four asthmarelated phenotypes: asthma, atopic asthma, BHR and strict asthma, respectively, and we also found these associations in the Danish population. The UK and Danish populations were independent and one would not necessarily expect to see the same SNP associations in both populations, because of the differing population histories. However, when polymorphisms within a gene are significantly associated in both samples, this result constitutes a gene-level replication of association. The markers which showed the most significant association were located in the haplotype block (Figure 1 ) in the UK and Danish populations.
Among the significant SNPs, SNP À731A/G had the lowest P-values with the four phenotypes in the UK population. These P-values were significant even after the Bonferroni correction for the number of markers tested (P-value threshold ¼ 0.05/4 ¼ 0.0125). The Pvalues for asthma, BHR and strict asthma were significant even after the most stringent correction for the number of markers and the number of phenotypes analyzed (P-value threshold ¼ 0.05/16 ¼ 0.0031). An intronic polymorphism ( þ 6541C/T) demonstrated the strongest significance in the Danish population. The P-values for asthma and BHR were significant after the Bonferroni correction for the number of markers analyzed (Po0.0125). In the UK population, six significant associations with two and three marker haplotype windows each and two associations with four marker windows were identified. The haplotype involving two markers in the promoter regions (À731A/G and À338G/ A) showed highly significant association with asthma, BHR and strict asthma and the P-values were significant after the most stringent Bonferroni correction (P-value threshold ¼ 0.05/24 ¼ 0.0021) for the number of haplotypes tested and the number of phenotypes analyzed.
Four genetic association studies on PTGDR and asthma are reported in the literature. Noguchi et al. 12 did not detect significant association of SNP À2C/T with asthma in the Japanese population. Oguma et al. 10 found the significant associations with the SNP À549C with asthma in the both Caucasian and African American populations and SNP À441T with asthma in the Caucasian population. Sanz et al.
11 detected the signifi- Haplotypes with a global Po0.05 are shown. P-specific represents the P-value of the most significant haplotype.
Haplotype frequency represents the frequency of the most significant haplotype. The relative position of the SNPs in the haplotype combinations corresponds to the SNPs ids given in Table 1 .
cant association of SNP À197T/C with asthma in the Spanish Caucasian population. Tsai et al. 13 did not detect any significant associations of SNPs À197T/C, À441C/T, À549T/C, þ 367C/A, þ 894G/A and þ 1044G/A with asthma in the Mexican, Puerto Rican, and African American populations. In this study, we report the significant replicated associations of PTGDR with asthma and asthma-related phenotypes in the two independent populations.
One of the associated polymorphisms (À731A/G) is located in the promoter region of PTGDR gene and may be functionally implicated in regulating the transcription of PTGDR. Several studies indicated that the PTGDR variants in the promoter have functional impact on the expression of PTGDR. 10, 11 The promoter SNP haplotypes (À549T/C, À441C/T, À197T/C) are shown to modify the PTGDR gene expression by altering the binding sites of the transcription factors, C/EBPb and members of the Sp and GATA families. 10 These transcription factors binding to the promoter are important for PTGDR transcription and the different SNPs change their binding efficiencies. 10 The significant SNPs of PTGDR, such as SNP 1 (À731A/G) located in its promoter region, may play a role in developing asthma through the mechanism of modifying the PTGDR gene transcription.
Our study has several strengths. First, we recruited the two large family-based populations, which have enough power to detect the associations with modest genetic effects. Using a relatively smaller sample size is often a factor leading to failure to detect and replicate associations across studies. For example, Noguchi et al. 12 did not detect the significant associations between the PTGDR variants and the asthma-related phenotypes in a small Japanese population; similarly, with small Mexican, Puerto Rican and African American populations, Tsia et al. failed to replicate the significant associations that Oguma et al. demonstrated. 10, 13 Second, our study was based on a family-based design and the significant associations from family studies are unlikely to be spurious due to population stratification. Third, the most significant SNPs in the two populations and the most significant haplotypes still remained significant after stringent Bonferroni multiple corrections, so the possibility that our results are false positive is substantially reduced. Fourth, our finding that PTGDR was associated with the four different asthma-related phenotypes suggests that our results are robust. To date, in all reported asthma association studies, only very few genes were found to have consistent associations with several asthma related phenotypes. 15 On the other hand, our study has several limitations. First, we genotyped only four SNPs in the PTGDR gene and used different SNPs in this study compared to others. Second, we did not find the associations between the same SNPs and the same phenotypes in the both populations. One reason could be the genetic heterogeneity of asthma; for example, three risk alleles in the four SNPs tested are different in the two populations, displaying a strong genetic heterogeneity (Table 2 ). However, the markers which showed the most significant association were located in the same haplotype block (Figure 1 ) in the UK and the Danish populations. In addition, the interactions of gene and environment, which are important in both initiating and exacerbating asthma, also vary in different populations. A gene's replication can occur from dissimilar polymorphisms in the same gene and even various alleles of the same variant. 16 Despite the limitations in our study, using two European Caucasian populations, our results replicate the finding of the significant associations of PTGDR in different SNPs with the asthma-related phenotypes in the American and Spanish Caucasian populations. 10, 11 Second, the age of parents and siblings were different in the family sets used in the analysis (see Table 4 for details). The primary analysis was performed in a pediatric/adolescent asthma population (mean age 14 years for siblings) while the replication analysis was performed in an adolescent/adult population (mean age 28 years for siblings). This can be viewed as an advantage rather than a limitation, since the replicated results can be applied to a broader asthmatic population. The phenotypic dissimilarity also substantiate the analysis of the data in these populations separately rather than a pooled analysis.
In conclusion, significant evidence of association between the polymorphisms in PTGDR gene and asthma-related phenotypes were identified in the two Caucasian populations. Further functional studies are needed to clarify the role of PTGDR variants in the patho-physiology of asthma.
Materials and methods
Study populations
Two sets of asthma families were evaluated for the genetic association studies. The primary study popula- 17, 18 Appropriate institutional review boards approved the studies and appropriate informed consent was obtained from the human subjects. The clinical characteristics of the ascertained families are shown in Table 4 .
The following phenotypes were evaluated. (1) Asthma was diagnosed by a participating physician examining the patients. (2) Atopic asthma: Atopic asthma was defined as having physician's diagnosis of asthma and at least one positive skin allergen test. (3) BHR was defined as a positive methacholine response (X20% reduction in FEV 1 ) at or below 8 mg/ml of methacholine. (4) Strict asthma was defined by an algorithm described by Barnes et al.:
19 two or more classical asthma symptoms (cough, wheeze and shortness of breath) and a positive methacholine challenge test (20% or more reduction in FEV 1 at or below 16 mg/ml of methacholine).
Genotyping
Four SNPs À731A/G, À338G/A, þ 6541C/T and þ 6651C/T within PTGDR gene were selected for genotyping. These SNPs were genotyped by a modification of the single base chain extension (SBCE) assay described previously. 20 Parental genotype data were used to assess Hardy-Weinberg equilibrium with an exact method. All SNPs from each population were in Hardy-Weinberg equilibrium. The PedCheck program was used to detect Mendelian inconsistencies in the genotype data from each family population. 21 No genotyping inconsistencies were detected.
Statistical analysis
FBAT version 1.7.1 22 was used for the family-based SNP association analysis with four phenotypes. Bi-allelic tests were conducted for SNPs using an additive genetic model. P-values o0.05 from the analyses were considered statistically significant. Haplotype analyses were conducted by using the HBAT function of the FBAT program with Monte Carlo sampling in the family data. 23 Using a SNP sliding window approach (adjacent two, three and four SNPs), the results of global and haplotype-specific statistics were reported. The LD structure was examined with the program, Haploview. 24 The r 2 for each pair of SNPs was calculated and haplotype blocks were defined by using confidence intervals algorithm. 25 We estimated the power of two populations to detect association using PBAT version 3.5 26 with the following parameters: allele frequency of the disease gene ¼ 0.1, population prevalence of the disease ¼ 0.06, odds ratio ¼ 1.6, allele frequency of the marker ¼ 0.2 and significant level ¼ 0.01. The estimated powers of two populations were greater than 80% with the additive model.
